Table of Contents
ISRN Oncology
Volume 2011, Article ID 219064, 6 pages
http://dx.doi.org/10.5402/2011/219064
Review Article

Lymph Node Staging with Choline PET/CT in Patients with Prostate Cancer: A Review

1SCDU Medicina Nucleare 2, ASO S. Giovanni Battista, Corso Bramante, 88, 10126 Torino, Italy
2Centro PET, IRMET SpA, Via Onorato Vigliani, 89/A, 10138 Torino, Italy

Received 14 October 2011; Accepted 13 November 2011

Academic Editor: A. E. Bilsland

Copyright © 2011 Andrea Skanjeti and Ettore Pelosi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Pelosi, V. Arena, A. Skanjeti et al., “Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer,” Radiologia Medica, vol. 113, no. 6, pp. 895–904, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Giovacchini, M. Picchio, E. Coradeschi et al., “Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 2, pp. 301–309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Castellucci, C. Fuccio, D. Rubello et al., “Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 1, pp. 55–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Pucar, T. Sella, and H. Schöder, “The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery,” Current Opinion in Urology, vol. 18, no. 1, pp. 87–97, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. H. Kawachi, R. R. Bahnson, M. Barry et al., “Prostate cancer early detection: clinical practice guidelines in oncology: prostate cancer early detection,” Journal of the National Comprehensive Cancer Network, vol. 8, no. 2, pp. 240–262, 2010. View at Google Scholar · View at Scopus
  6. G. Giovacchini, M. Picchio, V. Scattoni et al., “PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 6, pp. 1106–1116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Tuncel, M. Souvatzoglou, K. Herrmann et al., “[11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer,” Nuclear Medicine and Biology, vol. 35, no. 6, pp. 689–695, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. B. Apolo, N. Pandit-Taskar, and M. J. Morris, “Novel tracers and their development for the imaging of metastatic prostate cancer,” Journal of Nuclear Medicine, vol. 49, no. 12, pp. 2031–2041, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Beheshti, W. Langsteger, and I. Fogelman, “Prostate cancer: role of SPECT and PET in imaging bone metastases,” Seminars in Nuclear Medicine, vol. 39, no. 6, pp. 396–407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Hara, N. Kosaka, and H. Kishi, “PET imaging of prostate cancer using carbon-11-choline,” Journal of Nuclear Medicine, vol. 39, no. 6, pp. 990–995, 1998. View at Google Scholar · View at Scopus
  11. G. Smith, Y. Zhao, J. Leyton et al., “Radiosynthesis and pre-clinical evaluation of [18F]fluoro-[1,2-2H4]choline,” Nuclear Medicine and Biology, vol. 38, no. 1, pp. 39–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. T. R. DeGrado, R. E. Coleman, S. Wang et al., “Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer,” Cancer Research, vol. 61, no. 1, pp. 110–117, 2001. View at Google Scholar · View at Scopus
  13. E. Pelosi, C. Messa, S. Sironi et al., “Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 7, pp. 932–939, 2004. View at Google Scholar · View at Scopus
  14. T. Hara, N. Kosaka, and H. Kishi, “Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging,” Journal of Nuclear Medicine, vol. 43, no. 2, pp. 187–199, 2002. View at Google Scholar · View at Scopus
  15. T. Hara, A. Bansal, and T. R. DeGrado, “Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells,” Nuclear Medicine and Biology, vol. 33, no. 8, pp. 977–984, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. D. T. Price, R. E. Coleman, R. P. Liao, C. N. Robertson, T. J. Polascik, and T. R. DeGrado, “Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer,” Journal of Urology, vol. 168, no. 1, pp. 273–280, 2002. View at Google Scholar · View at Scopus
  17. A. J. Breeuwsma, J. Pruim, M. M. Jongen et al., “In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 6, pp. 668–673, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Fei, H. Wang, C. Wu, and S. M. Chiu, “Choline PET for monitoring early tumor response to photodynamic therapy,” Journal of Nuclear Medicine, vol. 51, no. 1, pp. 130–138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Davoodpour, M. Bergström, and M. Landström, “Effects of 2-methoxyestradiol on proliferation, apoptosis and PET-tracer uptake in human prostate cancer cell aggregates,” Nuclear Medicine and Biology, vol. 31, no. 7, pp. 867–874, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Farsad, R. Schiavina, P. Castellucci et al., “Detection and localization of prostate cancer: correlation of 11C-choline PET/CT with histopathologic step-section analysis,” Journal of Nuclear Medicine, vol. 46, no. 10, pp. 1642–1649, 2005. View at Google Scholar · View at Scopus
  21. G. Martorana, R. Schiavina, B. Corti et al., “11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy,” Journal of Urology, vol. 176, no. 3, pp. 954–960, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Testa, R. Schiavina, R. Lodi et al., “Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT,” Radiology, vol. 244, no. 3, pp. 797–806, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Kotzerke, J. Prang, B. Neumaier et al., “Experience with carbon-11 choline positron emission tomography in prostate carcinoma,” European Journal of Nuclear Medicine, vol. 27, no. 9, pp. 1415–1419, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. S. N. Reske, N. M. Blumstein, B. Neumaier et al., “Imaging prostate cancer with 11C-choline PET/CT,” Journal of Nuclear Medicine, vol. 47, no. 8, pp. 1249–1254, 2006. View at Google Scholar · View at Scopus
  25. L. Rinnab, N. M. Blumstein, F. M. Mottaghy et al., “11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer,” BJU International, vol. 99, no. 6, pp. 1421–1426, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. A. Kwee, H. Wei, I. Sesterhenn, D. Yun, and M. N. Coel, “Localization of primary prostate cancer with dual-phase 18F- fluorocholine PET,” Journal of Nuclear Medicine, vol. 47, no. 2, pp. 262–269, 2006. View at Google Scholar · View at Scopus
  27. S. A. Kwee, M. N. Coel, J. Lim, and J. P. Ko, “Prostate cancer localization with 18 fluorine fluorocholine positron emission tomography,” Journal of Urology, vol. 173, no. 1, pp. 252–255, 2005. View at Google Scholar · View at Scopus
  28. X. Li, Q. Lio, M. Wang et al., “C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions,” Clinical Nuclear Medicine, vol. 33, no. 10, pp. 671–676, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. D. B. Husarik, R. Miralbell, M. Dubs et al., “Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 2, pp. 253–263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Picchio, C. Messa, C. Landoni et al., “Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography,” Journal of Urology, vol. 169, no. 4, pp. 1337–1340, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Giovacchini, M. Picchio, E. Coradeschi et al., “Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 6, pp. 1065–1073, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Castellucci, C. Fuccio, C. Nanni et al., “Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy,” Journal of Nuclear Medicine, vol. 50, no. 9, pp. 1394–1400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Fuccio, P. Castellucci, R. Schiavina et al., “Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy,” Annals of Nuclear Medicine, vol. 24, no. 6, pp. 485–492, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. S. N. Reske, N. M. Blumstein, and G. Glatting, “[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 9–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Beheshti, R. Vali, P. Waldenberger et al., “The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT,” Molecular Imaging and Biology, vol. 11, no. 6, pp. 446–454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Beheshti, W. Langsteger, and I. Fogelman, “Prostate cancer: role of SPECT and PET in imaging bone metastases,” Seminars in Nuclear Medicine, vol. 39, no. 6, pp. 396–407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Wang, H. Vees, R. Miralbell et al., “18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer,” Radiotherapy and Oncology, vol. 93, no. 2, pp. 220–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Niyazi, P. Bartenstein, C. Belka, and U. Ganswindt, “Choline PET based dose-painting in prostate cancer—modelling of dose effects,” Radiation Oncology, vol. 5, p. 23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Pinkawa, C. Attieh, M. D. Piroth et al., “Dose-escalation using intensity-modulated radiotherapy for prostate cancer—evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost,” Radiotherapy and Oncology, vol. 93, no. 2, pp. 213–219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. S. A. Kwee, M. N. Coel, B. H. Ly, and J. Lim, “18F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer,” Annals of Nuclear Medicine, vol. 23, no. 6, pp. 541–548, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. P. U. Malmström, “Lymph node staging in prostatic carcinoma revisited,” Acta Oncologica, vol. 44, no. 6, pp. 593–598, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Beheshti, L. Imamovic, G. Broinger et al., “18F choline PET0/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients,” Radiology, vol. 254, no. 3, pp. 925–933, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Schiavina, V. Scattoni, P. Castellucci et al., “11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms,” European Urology, vol. 54, no. 2, pp. 392–401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. M. H. Poulsen, K. Bouchelouche, O. Gerke et al., “[18F]-fluorocholine positron-emissioncomputed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study,” BJU International, vol. 106, no. 5, pp. 639–643, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. I. J. De Jong, J. Pruim, P. H. Elsinga, W. Vaalburg, and H. J. Mensink, “Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-cholme PET,” Journal of Nuclear Medicine, vol. 44, no. 3, pp. 331–335, 2003. View at Google Scholar · View at Scopus
  46. T. Steuber, T. Schlomm, H. Heinzer et al., “[F18]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study,” European Journal of Cancer, vol. 46, no. 2, pp. 449–455, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Häcker, S. Jeschke, K. Leeb et al., “Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection,” Journal of Urology, vol. 176, no. 5, pp. 2014–2019, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Budiharto, S. Joniau, E. Lerut et al., “Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases,” European Urology, vol. 60, no. 1, pp. 125–130, 2011. View at Publisher · View at Google Scholar
  49. B. Scher, M. Seitz, W. Albinger et al., “Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 1, pp. 45–53, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. A. J. Breeuwsma, J. Pruim, A. C. M. van den Bergh et al., “Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using 11C-choline positron emission tomography,” International Journal of Radiation Oncology Biology Physics, vol. 77, no. 1, pp. 160–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. B. J. Krause, M. Souvatzoglou, M. Tuncel et al., “The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 18–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Rinnab, F. M. Mottaghy, N. M. Blumstein et al., “Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer,” BJU International, vol. 100, no. 4, pp. 786–793, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Schilling, H. P. Schlemmer, P. H. Wagner et al., “Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer,” BJU International, vol. 102, no. 4, pp. 446–451, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Cimitan, R. Bortolus, S. Morassut et al., “[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 12, pp. 1387–1398, 2006. View at Publisher · View at Google Scholar · View at Scopus